InteRNA Enters Into Agreement With Dana-Farber Cancer Institute

InteRNA Technologies and the Dana-Farber Cancer Institute have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

Under the collaboration with William Hahn, associate professor of department of medical oncology, InteRNA’s lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in diverse cancer pathways.

Roel Schaapveld, CEO of InteRNA, said: “We are very excited about this collaboration with Dr. Hahn, a cancer investigator, and the Dana-Farber, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of cancer”

Hahn of Dana-Farber Cancer Institute, said: “These functional screens hold great promise to help us better understand the roles of miRNAs in cancer and to identify potential treatment targets.”